Gain Therapeutics, Inc.
GANXNasdaqCIK 1819411HealthcareFiscal year ends Dec 31
Reports and events: 99 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2817:00 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-26-119673 |
| 2026-10-0109:16 ET | 8-K | 8.01 Other events | 0001104659-26-112624 |
| 2026-09-2816:30 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001104659-26-111391 |
| 2026-08-1116:07 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001104659-26-094048 |
| 2026-08-1116:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-094041 |
| 2026-07-1607:53 ET | 8-K | 8.01 Other events | 0001104659-26-084086 |
| 2026-06-2916:21 ET | 8-K | 8.01 Other events | 0001104659-26-078848 |
| 2026-06-2517:00 ET | 8-K | 5.07 Shareholder vote results | 0001104659-26-077820 |
| 2026-05-2609:26 ET | 8-K | 8.01 Other events | 0001104659-26-066062 |
| 2026-05-1116:08 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001104659-26-058649 |
| 2026-05-1116:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-058636 |
| 2026-04-2816:45 ET | DEF 14A | Proxy statementPeriod 2026-06-24 | 0001104659-26-050431 |
| 2026-03-2616:07 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001104659-26-035188 |
| 2026-03-2616:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-035174 |
| 2026-03-1808:51 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-029968 |
| 2026-02-0316:25 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-009747 |
| 2025-12-1809:00 ET | 8-K | 8.01 Other events | 0001104659-25-122353 |
| 2025-11-2816:03 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-116947 |
| 2025-11-1216:09 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001104659-25-110347 |
| 2025-11-1216:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-110343 |
| 2025-10-1416:56 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-25-099343 |
| 2025-10-0916:30 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001104659-25-098376 |
| 2025-10-0617:01 ET | 8-K | 8.01 Other events | 0001104659-25-097153 |
| 2025-08-1216:05 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001558370-25-011220 |
| 2025-08-1216:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001558370-25-011218 |
| 2025-07-1707:30 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-25-068530 |
| 2025-06-3016:30 ET | 8-K | 8.01 Other events | 0001104659-25-064145 |
| 2025-06-2417:09 ET | 8-K | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-25-062162 |
| 2025-05-1416:08 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001558370-25-007747 |
| 2025-05-1416:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001558370-25-007744 |
| 2025-04-2916:05 ET | DEF 14A | Proxy statementPeriod 2025-06-24 | 0001558370-25-005829 |
| 2025-04-1016:49 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-033797 |
| 2025-03-2716:21 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001558370-25-003823 |
| 2025-03-2716:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001558370-25-003807 |
| 2025-02-0616:50 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-25-010148 |
| 2025-01-1517:00 ET | 8-K | 3.01 Delisting notice | 0001104659-25-003801 |
| 2025-01-0717:00 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-25-001711 |
| 2024-12-2308:30 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-131084 |
| 2024-11-1416:07 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001558370-24-015709 |
| 2024-11-1416:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001558370-24-015705 |
| 2024-10-2117:22 ET | 8-K | 8.01 Other events | 0001104659-24-110287 |
| 2024-10-0816:30 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-107052 |
| 2024-09-0617:00 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-24-097781 |
| 2024-08-0816:05 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001558370-24-011589 |
| 2024-08-0816:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001558370-24-011585 |
| 2024-07-1217:24 ET | 8-K | 3.01 Delisting notice | 0001104659-24-079601 |
| 2024-07-0917:18 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-078600 |
| 2024-06-2817:00 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-24-076341 |
| 2024-06-2517:20 ET | 8-K | 5.07 Shareholder vote results | 0001104659-24-074822 |
| 2024-06-1416:40 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-24-071801 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 30, 2026, 17:20 ET. Listed shows no prices and gives no investment advice.